Cargando…

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma

Anti-CD30 CAR-T is a potent candidate therapy for relapsed/refractory (r/r) CD30+ lymphomas with therapy limitations, and the efficacy needed to be further improved. Herein a multi-center phase II clinical trial (NCT03196830) of anti-CD30 CAR-T treatment combined with PD-1 inhibitor in r/r CD30+ lym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sang, Wei, Wang, Xiangmin, Geng, Hongzhi, Li, Tianci, Li, Dashan, Zhang, Bingpei, Zhou, Yi, Song, Xuguang, Sun, Cai, Yan, Dongmei, Li, Depeng, Li, Zhenyu, Li, Caixia, Xu, Kailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010867/ https://www.ncbi.nlm.nih.gov/pubmed/35432352 http://dx.doi.org/10.3389/fimmu.2022.858021

Ejemplares similares

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy
por: Chen, Wei, et al.
Publicado: (2021)

2718. Prevalence of Infections Following Anti-CD30 Targeted Chimeric Antigen Receptor T-cell Therapy for Relapsed and Refractory Lymphoma
por: Mohnasky, Michael C, et al.
Publicado: (2023)

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
por: Sang, Wei, et al.
Publicado: (2020)

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
por: Tschernia, Nicholas P, et al.
Publicado: (2023)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
por: Yang, Qing-Ming, et al.
Publicado: (2014)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
por: Ding, Jing, et al.
Publicado: (2022)

Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
por: Lu, Yanyan, et al.
Publicado: (2023)

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
por: Wang, Yucai, et al.
Publicado: (2018)

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
por: Tu, Sanfang, et al.
Publicado: (2019)

PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
por: Zhang, Ying, et al.
Publicado: (2023)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
por: Zhang, Ying, et al.
Publicado: (2021)

P1236: EFFICACY AND TOXICITY FOR CD7 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA
por: Hu, K., et al.
Publicado: (2022)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
por: Yegya-Raman, Nikhil, et al.
Publicado: (2023)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
por: Wang, Xue, et al.
Publicado: (2022)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

P1466: CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED T CELL MALIGNANCIES
por: Zhang, Y., et al.
Publicado: (2022)

P1389: A NOVEL AND SUCCESSFUL CD7-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR REFRACTORY/RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)
por: Zhang, Xian, et al.
Publicado: (2023)

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
por: Lobastova, Liudmila, et al.
Publicado: (2021)

Anti-CD30-targeted gold nanoparticles for photothermal therapy of L-428 Hodgkin’s cell
por: Qu, Xiaochao, et al.
Publicado: (2012)

Utilizing CD30 expression as a rational target for therapy of lymphoma
por: Kim, Won Seog
Publicado: (2012)

Effectiveness and safety of CD22 and CD19 dual‐targeting chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory B‐cell malignancies: A meta‐analysis
por: Nguyen, Thi Thuy, et al.
Publicado: (2023)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022)

A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb
por: Wu, Yang, et al.
Publicado: (2021)

Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2023)

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
por: Kim, Miso, et al.
Publicado: (2021)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

CD30(+) lymphomatoid skin toxicity secondary to ipilimumab
por: Bush, Amelia E., et al.
Publicado: (2020)

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
por: Liu, Sining, et al.
Publicado: (2023)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report
por: Huang, Chen, et al.
Publicado: (2020)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity
por: Shen, Yijun, et al.
Publicado: (2019)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c7buc0bjfj18lajlvcdekqlcn1